ReviewWorld journal of gastrointestinal pharmacology and therapeutics2025
Targeted nanoliposomal nutrient delivery for human health.
Review in World journal of gastrointestinal pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional nutritional supplements frequently demonstrate limited clinical effectiveness due to the harsh milieu of the gastrointestinal tract, inefficient trans-epithelial transport, and rapid systemic clearance. Nanoliposomal delivery platforms - lipid bilayer vesicles on the nanometer scale - have attracted attention as an adaptive strategy to shield sensitive nutrients, navigate biological barriers, and deliver payloads directly to target tissues or even sub-cellular organelles. Despite a growing body of literature, a consolidated appraisal of design principles, targeting modalities, and translational hurdles is still needed to guide future nutraceutical innovation. We aim to: (1) Summarize the physicochemical foundations of nanoliposomal nutrient carriers; (2) Delineate state-of-the-art approaches for organ-specific and organelle-specific targeting, with particular emphasis on renal and mitochondrial delivery; (3) Evaluate current evidence supporting therapeutic benefits in cardiometabolic, neuroprotective, and renal-repair contexts; and (4) Map unresolved challenges - including manufacturing scale-up, cost, and regulatory oversight - to inform a roadmap for clinical translation. A systematic literature search was performed across PubMed, Web of Science, and Scopus through May 2025 using Boolean combinations of "nanoliposome", "nutrient", "targeted delivery", "bioavailability", and organ-specific terms (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.